A101-AB-MMAE

A101-AB-MMAE is an experimental mesothelin-targeted nanobody-drug conjugate (NDC) designed for the treatment of pancreatic ductal adenocarcinoma (PDAC). It utilizes a camelid-derived VHH nanobody, A101, which binds with high affinity to mesothelin (MSLN), a cell-surface glycoprotein frequently overexpressed in PDAC. The nanobody is conjugated to the potent antimitotic agent monomethyl auristatin E (MMAE) via a novel, exclusively intracellularly cleavable small molecule linker known as AB. This NDC format is intended to overcome the limitations of traditional antibody-drug conjugates in PDAC, such as poor penetration of the dense tumor stroma, by leveraging the smaller size of the nanobody for improved biodistribution and tumor uptake. Preclinical data indicates that A101-AB-MMAE exhibits superior efficacy and specificity in MSLN-positive tumor models compared to conjugates using standard linkers.